View Older Stories View More Recent Stories

May 18, 2020 08:01AM Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
May 15, 2020 10:36AM Seelos Therapeutics (SEEL) Announces Judith Dunn to Board
May 15, 2020 10:30AM Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 15, 2020 10:30AM Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 15, 2020 07:32AM Seelos Therapeutics (SEEL) Receives Rare Pediatric Disease Designation for SLS-005 in Sanfilippo Syndrome
May 15, 2020 07:30AM Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
May 15, 2020 07:30AM Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
May 12, 2020 08:01AM Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 12, 2020 08:01AM Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 4, 2020 08:07AM Seelos Therapeutics (SEEL) Receives Notice of Allowance for Additional US Patent for Trehalose
May 4, 2020 08:01AM Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
May 4, 2020 08:01AM Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
Apr 30, 2020 01:33PM Seelos Therapeutics (SEEL) Confirms Orphan Drug Designation for SLS-005 (Trehalose)
Apr 30, 2020 01:31PM Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
Apr 30, 2020 01:31PM Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
Apr 8, 2020 09:04AM Seelos Therapeutics (SEEL) Announces 1Q20 Business Update and Pipeline Developments
Apr 8, 2020 09:01AM Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
Apr 8, 2020 09:01AM Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
Mar 24, 2020 08:06AM Seelos Therapeutics (SEEL) Reports Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Mar 24, 2020 08:01AM Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Mar 24, 2020 08:01AM Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Mar 16, 2020 04:30PM Seelos Therapeutics Announces Closing of Public Offering of Common Stock
Mar 16, 2020 04:30PM Seelos Therapeutics Announces Closing of Public Offering of Common Stock
Mar 12, 2020 05:53AM Seelos Therapeutics (SEEL) Prices 7.5M Share Common Offering at $0.60/Sh
Mar 11, 2020 08:30PM Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock
Mar 11, 2020 08:30PM Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock
Mar 11, 2020 04:15PM Seelos Therapeutics (SEEL) Announces Proposed Public Offering of Common Stock
Mar 11, 2020 04:15PM Seelos Therapeutics Announces Proposed Public Offering of Common Stock
Mar 11, 2020 04:15PM Seelos Therapeutics Announces Proposed Public Offering of Common Stock
Mar 11, 2020 08:11AM Seelos Therapeutics (SEEL) Announces EMA Guidance to Design Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
Mar 11, 2020 08:01AM Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
Mar 11, 2020 08:01AM Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
Mar 6, 2020 08:02AM Seelos Therapeutics (SEEL) Receives Notice of Allowance for Composition of Matter Patent for SLS-007
Mar 6, 2020 08:01AM Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
Mar 6, 2020 08:01AM Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
Mar 3, 2020 04:05PM ServiceSource Announces Four New Appointments to Board of Directors
Feb 26, 2020 08:03AM Seelos Therapeutics (SEEL) Reports Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Feb 26, 2020 08:01AM Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Feb 26, 2020 08:01AM Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Feb 19, 2020 08:02AM Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
Feb 19, 2020 08:02AM Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
Feb 13, 2020 04:30PM Seelos Therapeutics Announces Closing of Public Offering of Common Stock
Feb 13, 2020 04:30PM Seelos Therapeutics Announces Closing of Public Offering of Common Stock
Feb 11, 2020 05:52AM Seelos Therapeutics (SEEL) Prices 6.667M Share Common Offering at $0.75/Sh
Feb 10, 2020 08:00PM Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
Feb 10, 2020 08:00PM Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
Jan 28, 2020 08:05AM Seelos Therapeutics (SEEL) Announces Update to Parkinson’s Disease Program SLS-007
Jan 28, 2020 08:02AM Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
Jan 28, 2020 08:02AM Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
Jan 22, 2020 07:32AM Seelos Therapeutics (SEEL) Reports Updates to SLS-005 (trehalose) Programs for Europe and U.S.
View More Recent Stories View Older Stories